Glenmark Pharmaceuticals declares interim dividend, reconstitutes key committees

Glenmark Pharmaceuticals' board of directors approved an interim dividend of ₹2.50 per equity share for the financial year 2025-26. This dividend, based on a face value of ₹1/- per equity share, amounts to ₹705.50 million. The record date for the dividend payment is Friday, October 3, 2025, with payment expected within 30 days.

In addition to the dividend, the board also approved the reconstitution of several key committees, effective October 1, 2025. Ms. Sona Saira Ramasastry will chair the Stakeholders Relationship Committee, while Mr. Dipankar Bhattacharjee will lead the Risk Management Committee.

Mr. Glenn Saldanha has been appointed chairman of the ESG (Environmental, Social and Governance) Committee. These changes aim to enhance the company's governance structure and strategic oversight.